Other molecular markers have been postulated for platinum-based chemotherapy in NSCLC, such as excision repair cross-complementation group 1 (ERCC1) protein expression in tumor tissue [13] and ERCC1 germline polymorphisms [14]. The gene discussed is ERCC1; the disease is non-small cell lung carcinoma.